The main human-derived tumor models (cell lines, xenografts and organoids) do not preserve the immune cells of the tumor from which they are derived. This limits the ability to effectively predict the...
9397-2677 Québec inc.
7 enregistrements totalisant 350,154.50 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $350,155 | 7 enregistrements |
Enregistrements
The project aims to establish the utility of the technology to test, in a single ex vivo experiment, several combinations of immunotherapies to identify the most effective one, and to screen murine tu...
This project under the International Co-Innovation Action Program (ICAP) will prepare the firm to engage in future international co-innovation initiatives in Japan.
This project aims to develop an ex vivo platform for the development of cancer immunotherapies and the discovery of predictive biomarkers. The project includes the development of protocols for 1) pres...
The aim of the project is to identify the optimal doses for five new treatments on human tumours explants by conducting efficacy tests on spheroids from three different cell lines.
The project aims to develop the market strategy for two new market segments contemplated for the next few years, among other things, to confirm the value proposition for these two different segments.
The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Rese...